This COVID-19 related work is a collaboration between the Divisions of Cardiology and Infectious Disease, with pivotal contributions from our internal medicine residents.
The journal, ESC Heart Failure, is an official publication of the Heart Failure Association of the European Society of Cardiology.
This retrospective cohort study deals with the use of a cardiac biomarker, NT-proBNP (measured in routine blood samples) for risk stratification of patients admitted with COVID-19. The underlying hypothesis is that elevated NT-proBNP is a marker of vulnerability to volume overload because of combined heart, lung, and kidney stress during COVID-19. This Stony Brook group observed that In patients with COVID-19 and no history of heart failure, high admission NT-proBNP is associated with higher mortality and healthcare resources utilization. The investigator concluded that preventive strategies, related to fluid management, may be required for these patients -- a clinical hypothesis that requires further investigation.
Impact of a Cardiac Biomarker on Risk Stratification of Patients Hospitalized with Covid-19
Thank you to our Department of Medicine authors:
Jeanwoo Yoo1 , Prabhjot Grewal1, Jessica Hotelling1, Aikaterini Papamanoli2, Kerry Cao1, Simrat Dhaliwal1, Robin Jacob1, Azad Mojahedi1, Michelle E. Bloom3, Luis A. Marcos2, Hal A. Skopicki3 and Andreas P. Kalogeropoulos3*
1Department of Medicine, Stony Brook University, Stony Brook, NY, USA; 2Division of Infectious Diseases, Department of Medicine, Stony Brook University, Stony Brook, NY, USA; 3Division of Cardiology, Department of Medicine, Stony Brook University, Stony Brook, NY, USA
Please access this important publication here:
PDF version:
Web-based version:
https://onlinelibrary.wiley.com/doi/10.1002/ehf2.13548
